Furthermore, the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial reported an annual incidence of any overt bleeding of 14.15% and 16.40% for high-dose edoxaban and warfarin, respectively (HR 0.87, CI 0.82–0.92, p < 0.001) [8]. Here, F10 is linked to myocardial infarction.